Feng G, Valenti L, Wong VW, Fouad YM, Yilmaz Y, Kim W, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21:46–56

Article  PubMed  Google Scholar 

Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842–852

Article  PubMed  Google Scholar 

Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med. 2022;73:529–544

Article  CAS  PubMed  Google Scholar 

Mendez-Sanchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388–390

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209

Article  PubMed  Google Scholar 

Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74:989–991

Article  PubMed  Google Scholar 

Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016;48: e218

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3:1596–1607

Article  CAS  PubMed  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64

Article  PubMed  Google Scholar 

Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10:329–338

Article  PubMed  Google Scholar 

Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433

Article  CAS  PubMed  Google Scholar 

Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259–268

Article  PubMed  Google Scholar 

Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21:270

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196

Article  PubMed  PubMed Central  Google Scholar 

Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160–166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 2017;65:1132–1144

Article  CAS  PubMed  Google Scholar 

Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016;6: e013781

Article  PubMed  PubMed Central  Google Scholar 

Heida A, Gruben N, Catrysse L, Koehorst M, Koster M, Kloosterhuis NJ, et al. The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis. Mol Metab. 2021;54: 101349

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammoutene A, Laouirem S, Albuquerque M, Colnot N, Brzustowski A, Valla D, et al. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023;5: 100845

Article  PubMed  PubMed Central  Google Scholar 

Teng F, Jiang J, Zhang J, Yuan Y, Li K, Zhou B, et al. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. Metabolism. 2021;117: 154725

Article  CAS  PubMed  Google Scholar 

Gu Y, Duan S, Ding M, Zheng Q, Fan G, Li X, et al. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway. Phytomedicine. 2022;103: 154219

Article  CAS  PubMed  Google Scholar 

Yang B, Sun J, Liang S, Wu P, Lv R, He Y, et al. Prediction of Srebp-1 as a key target of Qing Gan San against MAFLD in rats via RNA-sequencing profile analysis. Front Pharmacol. 2021;12: 680081

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin H, Wang L, Liu Z, Long K, Kong M, Ye D, et al. Hepatic MDM2 causes metabolic associated fatty liver disease by blocking triglyceride-VLDL secretion via ApoB degradation. Adv Sci (Weinh). 2022;9: e2200742

Article  PubMed  Google Scholar 

Junli Z, Shuhan W, Yajuan Z, Xiaoling D, Jiahuan L, Keshu X. The role and mechanism of CREBH regulating SIRT3 in metabolic associated fatty liver disease. Life Sci. 2022;306: 120838

Article  PubMed  Google Scholar 

Ma C, Wang Z, Xia R, Wei L, Zhang C, Zhang J, et al. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2. Biomed Pharmacother. 2021;137: 111344

Article  CAS  PubMed  Google Scholar 

Wang J, Zhang F, Yang W, Gao D, Yang L, Yu C, et al. FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation. Faseb J. 2023;37: e22881

Article  CAS  PubMed  Google Scholar 

Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins’ efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Nutr. 2022;41:2195–2206

Article  CAS  PubMed  Google Scholar 

Ayada I, van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87: 104392

Article  CAS  PubMed  Google Scholar 

Zhang D, Ma Y, Liu J, Wang D, Geng Z, Wen D, et al. Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. Eur J Pharmacol. 2023;960: 176159

Article  CAS  PubMed  Google Scholar 

Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21:143-152.e143

Article  CAS  PubMed  Google Scholar 

Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33:424–442

Article  CAS  PubMed  Google Scholar 

Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367–378

Article  PubMed  Google Scholar 

Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 46-year cohort study in China. J Clin Endocrinol Metab. 2022;107:88–97

Article  PubMed  Google Scholar 

Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501,022 adult individuals. Gut. 2021;70:962–969

Article  CAS  PubMed  Google Scholar 

Fan X, Jiao G, Pang T, Wen T, He Z, Han J, et al. Ameliorative effects of mangiferin derivative TPX on insulin resistance via PI3K/AKT and AMPK signaling pathways in human HepG2 and HL-7702 hepatocytes. Phytomedicine. 2023;114: 154740

Article  CAS  PubMed